| Classification | SOC | Neonatal | PBLS | BLS | PALS | ALS | Spec Circ | PCAC | Education | Total | % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class (Strength) of Recommendation | |||||||||||
| 1: (strong) | 13 | 21 | 19 | 25 | 36 | 19 | 66 | 23 | 11 | 233 | 31 |
| 2a: (moderate) | 19 | 24 | 11 | 21 | 25 | 18 | 84 | 6 | 9 | 217 | 29 |
| 2b: (weak) | 6 | 18 | 6 | 15 | 45 | 29 | 58 | 41 | 16 | 234 | 31 |
| 3: No benefit (moderate) | 0 | 1 | 0 | 3 | 12 | 8 | 21 | 9 | 1 | 55 | 7 |
| 3: Harm (strong) | 0 | 3 | 1 | 3 | 2 | 5 | 6 | 0 | 1 | 21 | 3 |
| Totals | 38 | 67 | 37 | 67 | 120 | 79 | 235 | 79 | 38 | 760 | 100 |
| Level (Quality) of Evidence | |||||||||||
| A: (moderate) | 1 | 3 | 0 | 0 | 1 | 2 | 2 | 0 | 2 | 11 | 1 |
| B-R | 6 | 18 | 6 | 15 | 45 | 29 | 58 | 41 | 16 | 234 | 31 |
| B-NR | 0 | 1 | 0 | 3 | 12 | 8 | 21 | 9 | 1 | 55 | 7 |
| C-LD | 0 | 3 | 1 | 3 | 2 | 5 | 6 | 0 | 1 | 21 | 3 |
| C-EO | 0 | 3 | 1 | 3 | 2 | 5 | 6 | 0 | 1 | 21 | 3 |
| Totals | 38 | 67 | 37 | 67 | 120 | 79 | 235 | 79 | 38 | 760 | 100 |